Worsening of subacute lupus erythematosus induced by infliximab;Aggravation d'un lupus érythémateux subaigu sous infliximab

Annales de Dermatologie et de Venereologie

Volumn 132, Issue 4, 2005, Pages 349-353

  Vabre Latre, C M ^a   Bayle, P ^a   Marguery, M C ^a   Gadroy, A ^a   Durand, D ^b   Bazex, J ^a  

^a CHU PURPAN   (France)

^b CHU RANGUEIL   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHLOROQUINE; CYCLOPHOSPHAMIDE; DAPSONE; HYDROXYCHLOROQUINE; INFLIXIMAB; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXACILLIN; RO ANTIBODY; TUMOR NECROSIS FACTOR ALPHA ANTIBODY;

ADULT; ARTICLE; AUTOIMMUNE DISEASE; CASE REPORT; DISEASE EXACERBATION; DRUG CONTRAINDICATION; FEMALE; HUMAN; LUPUS ERYTHEMATOSUS; RHEUMATOID ARTHRITIS; SKIN LUPUS ERYTHEMATOSUS;

EID: 18744402180     PISSN: 01519638     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0151-9638(05)79281-4     Document Type: Article

References (18)

1. Devos SA, Van Den Bossche N, De Vos M, Naeyaert JM. Adverse Skin Reactions to Anti-TNF-α Monoclonal Antibody Therapy. Dermatology 2003;206:388-90.
2. Vergara G, Silvestre JF, Betlloch I, Vela P, Albares MP. Cutaneous drug eruption to infliximab: report of 4 cases with an interface dermatitis pattern. Arch Dermatol 2002;138:1258-9.
3. Callen JP. Drug-induced lupus erythematosus, a distinct syndrome that is frequently unrecognized. J Am Acad Dermatol 2001;45:315-6.
4. Srivastava M, Rencic A, Diglio G, Santana H, Bonitz P, Watson R et al. Drug induced, Ro/SSA-Positive cutaneus lupus erythematosus. Arch Dermatol 2003;139:45-9.
5. Charles PJ, Smeenk RJT, de Jong J, Feldmann M, Maini RN. Assessment of antibodies to double-stranded DNA induced in rheumatoid arthritis patients following treatment with infliximab, a monoclonal antibody to tumor necrosis factor α. Arthritis Rheum 2000;43:2383-90.
6. De Rycke L, Kruithof E, Van Damme N, Hoffmann IEA, Van Den Bossche N, Van Den Bossche F et al. Antinuclear antibodies following infliximab treatment in patients with rheumatoid arthritis or spondylarthropathy. Arthritis Rheum 2003;48:1015-23.
7. MJ De Brandt, J Sibilia, X Le Loet, S Prouzeau, B Fautrel, C Marcelli et al. Systemic lupus erythematosus induced by anti-TNF α therapy: a french national surgery. EULAR 2004;THU 0354.
8. Shackoor N, Michalska M, Harris CA, Block JA. Drug-induced systemic lupus erythematosus associated with etanercept therapy. Lancet 2002; 359:579-80.
9. Ali Y, Shah S. Infliximab-induced systemic lupus erythematosus. Ann Intern Med 2002;137:625-6.
10. Favalli EG, Sinigaglia L, Varenna M, Arnoldi C. Drug-induced lupus following treatment with infliximab in rheumatoid arthritis. Lupus 2002;11:753-5.
11. Ferraccioli GF, Assaloni R, Perin A. Drug-induced systemic lupus erythematosus and TNF-α blockers. Lancet 2002;360:645.
12. Klapman JB, Ene-Stroescu D, Becker MA, Hanauer SB. A lupus-like syndrome associated with infliximab therapy. Inflamm Bowel Dis 2003;9:176-8.
13. Debandt M, Vittecoq O, Descamps V, Le Loet X, Meyer O. Anti-TNF-alpha-induced systemic lupus syndrome. Clin Rheumatol 2003;22:56-61.
14. Brion PH, Mittal-Henkel A, Kalunian KC. Autoimmune skin rashes associated with etanercept for rheumatoid arthritis. Ann Intern Med 1999; 131:634.
15. Bleumink GS, ter Borg EJ, Ramselaar CG, Strickler BH. Etanercept-induced subacute cutaneous lupus erythematosus. Rheumatology 2001; 40:1317-9.
16. Cairns AP, Duncan MK, Hinder AE, Taggart AJ. New onset systemic lupus erythematosus in a patient receiving etanercept for rheumatoid arthritis. Ann Rheum Dis 2002;61:1031-2.
17. Swale VJ, Perret CM, Denton CP, Black CM, Rustin MHA. Etanercept-induced systemic lupus erythematosus. Clin Exp Dermatol 2003;28:604-7.
18. Fautrel B, Foltz V, Frances C, Bourgeois P, Rozenberg S. Regression of subacute cutaneous lupus erythematosus in a patient with rheumatoid arthritis treated with a biologic tumor necrosis factor alpha-blocking agent: comment on the article by Pisetsky and the letter from Aringer et al. Arthritis Rheum 2002;46:1408-9.